Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Oberg K ^a   Akerstrom G ^a   Rindi, G ^b   Jelic, S ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b CATHOLIC UNIVERSITY   (Italy)

^c INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; KI 67 ANTIGEN; OXALIPLATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CARCINOID; CARCINOID SYNDROME; EUROPE; FOLLOW UP; GASTROINTESTINAL TUMOR; GLUCAGONOMA; HUMAN; LIVER METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR CLASSIFICATION; VIPOMA;

ANTIBODIES, MONOCLONAL; CYTOTOXINS; EMBOLIZATION, THERAPEUTIC; EUROPE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GENERAL SURGERY; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RISK ASSESSMENT; SIROLIMUS; SOMATOSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954330417     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq192     Document Type: Article

References (19)

1. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
3. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407.
4. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
5. Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours. World Health Organization Histological Classification of Tumours, 2nd edition. New York: Springer 2000 38-74.
6. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000; (62 Suppl 1): 33-38.
7. Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
8. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21: 43-68.
9. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69-85.
10. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer 2005; 12: 1083-1092.
11. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surgeons 2003; 197: 29-37.
12. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87-109.
13. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/ chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 131-144.
14. Öberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; (12 Suppl 2): S111-S114.
15. Plöckinger U, Wiedenmann B. Neuroendocrine tumors: biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 145-162.
16. Rinke A, Müller H-H, Schade-Brittinger C et al. Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27: 4656-4663.
17. Van Essen M, Krenning EP, Kam BL et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009; 5: 382-393.
18. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 2007; 21: 163-172.
19. Klöppel G, Couvelard A, Perren A et al. ENETS guidelines for the standards of care in patients with neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2008 Dec 5.